A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose
in patients with a genetic CYP2D6 polymorphism. The investigators also plan to investigate
other genetic variations in the metabolism of tamoxifen.